S&P 500   2,992.36 (-0.19%)
DOW   26,856.93 (-0.63%)
QQQ   192.03 (-0.79%)
AAPL   236.13 (+0.36%)
FB   185.92 (-2.35%)
GOOGL   1,245.66 (-0.57%)
AMZN   1,763.32 (-1.35%)
CGC   20.00 (-3.66%)
NVDA   190.73 (-1.83%)
MU   43.47 (-4.46%)
BABA   170.36 (-3.67%)
GE   8.99 (-0.55%)
TSLA   256.90 (-1.94%)
AMD   30.81 (-1.06%)
T   38.23 (+1.08%)
F   9.29 (+1.98%)
PRI   124.22 (+0.12%)
NFLX   276.16 (-5.86%)
GILD   64.23 (-1.53%)
DIS   131.27 (-0.83%)
S&P 500   2,992.36 (-0.19%)
DOW   26,856.93 (-0.63%)
QQQ   192.03 (-0.79%)
AAPL   236.13 (+0.36%)
FB   185.92 (-2.35%)
GOOGL   1,245.66 (-0.57%)
AMZN   1,763.32 (-1.35%)
CGC   20.00 (-3.66%)
NVDA   190.73 (-1.83%)
MU   43.47 (-4.46%)
BABA   170.36 (-3.67%)
GE   8.99 (-0.55%)
TSLA   256.90 (-1.94%)
AMD   30.81 (-1.06%)
T   38.23 (+1.08%)
F   9.29 (+1.98%)
PRI   124.22 (+0.12%)
NFLX   276.16 (-5.86%)
GILD   64.23 (-1.53%)
DIS   131.27 (-0.83%)
Log in

Anthera Pharmaceuticals Stock Price, News & Analysis (OTCMKTS:ANTH)

$0.06
0.00 (0.00 %)
(As of 10/18/2019 02:30 PM ET)
Today's Range
$0.04
Now: $0.06
$0.06
50-Day Range
$0.04
MA: $0.06
$0.12
52-Week Range
$0.01
Now: $0.06
$0.10
Volume5,687 shs
Average Volume15,582 shs
Market Capitalization$1.54 million
P/E RatioN/A
Dividend YieldN/A
Beta4.04
Anthera Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development and commercialization of medicines for patients with unmet medical needs. It develops Sollpura, a non-porcine investigational pancreatic enzyme replacement therapy that is in Phase III clinical trial for the treatment of patients with exocrine pancreatic insufficiency; and Blisibimod, which is in Phase II clinical trial for the treatment of B-cell mediated autoimmune diseases, including immunoglobulin A nephropathy or IgA nephropathy. Read More…

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolOTCMKTS:ANTH
CUSIPN/A
Phone510-856-5600

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$140,000.00
Book Value($0.42) per share

Profitability

Miscellaneous

EmployeesN/A
Market Cap$1.54 million
Next Earnings DateN/A
OptionableOptionable

Receive ANTH News and Ratings via Email

Sign-up to receive the latest news and ratings for ANTH and its competitors with MarketBeat's FREE daily newsletter.


Anthera Pharmaceuticals (OTCMKTS:ANTH) Frequently Asked Questions

What is Anthera Pharmaceuticals' stock symbol?

Anthera Pharmaceuticals trades on the OTCMKTS under the ticker symbol "ANTH."

When did Anthera Pharmaceuticals' stock split? How did Anthera Pharmaceuticals' stock split work?

Anthera Pharmaceuticals shares reverse split before market open on Monday, May 1st 2017. The 1-8 reverse split was announced on Friday, April 28th 2017. The number of shares owned by shareholders was adjusted after the closing bell on Friday, April 28th 2017. An investor that had 100 shares of Anthera Pharmaceuticals stock prior to the reverse split would have 13 shares after the split.

How were Anthera Pharmaceuticals' earnings last quarter?

Anthera Pharmaceuticals Inc (OTCMKTS:ANTH) posted its quarterly earnings data on Monday, March, 5th. The biopharmaceutical company reported ($0.73) earnings per share (EPS) for the quarter, beating the Zacks' consensus estimate of ($0.82) by $0.09. View Anthera Pharmaceuticals' Earnings History.

Has Anthera Pharmaceuticals been receiving favorable news coverage?

News coverage about ANTH stock has been trending neutral this week, InfoTrie Sentiment Analysis reports. The research group identifies positive and negative media coverage by monitoring more than six thousand news and blog sources. The firm ranks coverage of public companies on a scale of negative five to five, with scores closest to five being the most favorable. Anthera Pharmaceuticals earned a news sentiment score of 0.2 on InfoTrie's scale. They also gave press coverage about the biopharmaceutical company a news buzz of 0.0 out of 10, indicating that recent media coverage is extremely unlikely to have an effect on the company's share price in the immediate future. View News Stories for Anthera Pharmaceuticals.

Who are some of Anthera Pharmaceuticals' key competitors?

What other stocks do shareholders of Anthera Pharmaceuticals own?

Who are Anthera Pharmaceuticals' key executives?

Anthera Pharmaceuticals' management team includes the folowing people:
  • Mr. Paul F. Truex, Exec. Chairman (Age 49)
  • Mr. John Craig Thompson, Pres, CEO & Director (Age 51)
  • Dr. Renee Martin Ph.D., Sr. VP of Medical Sciences (Age 49)
  • Dr. William R. Shanahan Jr., M.D., J.D., Chief Medical Officer & Sr. VP (Age 69)
  • Ms. May Liu, Chief Accounting Officer, Sr. VP of Fin. & Admin. and Compliance Officer (Age 42)

How do I buy shares of Anthera Pharmaceuticals?

Shares of ANTH can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

What is Anthera Pharmaceuticals' stock price today?

One share of ANTH stock can currently be purchased for approximately $0.06.

How big of a company is Anthera Pharmaceuticals?

Anthera Pharmaceuticals has a market capitalization of $1.54 million and generates $140,000.00 in revenue each year. View Additional Information About Anthera Pharmaceuticals.

What is Anthera Pharmaceuticals' official website?

The official website for Anthera Pharmaceuticals is http://www.anthera.com/.

How can I contact Anthera Pharmaceuticals?

Anthera Pharmaceuticals' mailing address is 25801 INDUSTRIAL BOULEVARD SUITE B, HAYWARD CA, 94545. The biopharmaceutical company can be reached via phone at 510-856-5600.


MarketBeat Community Rating for Anthera Pharmaceuticals (OTCMKTS ANTH)

Community Ranking:  2.5 out of 5 (star star half star)
Outperform Votes:  329 (Vote Outperform)
Underperform Votes:  318 (Vote Underperform)
Total Votes:  647
MarketBeat's community ratings are surveys of what our community members think about Anthera Pharmaceuticals and other stocks. Vote "Outperform" if you believe ANTH will outperform the S&P 500 over the long term. Vote "Underperform" if you believe ANTH will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 10/18/2019 by MarketBeat.com Staff

Featured Article: Trading Strategy

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel